CDK4/6 inhibition initiates cell cycle arrest by nuclear translocation of RB and induces a multistep molecular response

Keyphrases

• Nuclear Translocation 100%
• Cell Cycle Arrest 100%
• Molecular Response 100%
• Cyclin-dependent Kinase 4 (CDK4) 100%
• Molecular Mechanism 66%
• Bladder Cancer Cells 66%
• Clinical Trials 33%
• Therapeutic Efficacy 33%
• Monotherapy 33%
• RNA Sequencing (RNA-seq) 33%
• Standard of Care 33%
• Cancer Cells 33%
• Apoptosis 33%
• Treatment Regimen 33%
• Protein Family 33%
• Metastatic Breast Cancer 33%
• Therapy Response 33%
• Endocrine Therapy 33%
• Response to Therapy 33%
• Senescence 33%
• Resistance Mechanisms 33%
• Poor Response 33%
• G1 Arrest 33%
• SCF Complex 33%
• Response Mechanism 33%
• Importin 33%
• Rb Protein 33%
• Therapeutic Design 33%
• CDK4/6 Inhibitor Palbociclib 33%
• Lysosomal Biogenesis 33%
• PD Treatment 33%
• Gankyrin 33%

Biochemistry, Genetics and Molecular Biology

• Cancer Cell 100%
• Cell Cycle Arrest 100%
• Cell Cycle Checkpoint 100%
• Clinical Trial 33%
• Importin 33%
• Protein Family 33%
• RNA Sequence 33%
• Biogenesis 33%
• G1/S Transition 33%
• SCF Complex 33%
• Karyopherin 33%
• Programmed Cell Death 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Bladder Cancer 100%
• Endocrine Therapy 50%
• Clinical Trial 50%
• RNA-Sequencing 50%
• Palbociclib 50%
• Malignant Neoplasm 50%
• Metastatic Breast Cancer 50%
• Combination Therapy 50%
• Monotherapy 50%
• Karyopherin 50%